Navigation Links
Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--May 17, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that partners of the company will present new interim data from two phase I clinical trials of plasmid-based immunotherapies using Inovio's electroporation delivery technology at the Third International Conference on DNA Vaccines in Malaga, Spain, being held May 23-25, 2007 at the Torrequebrada Hotel. Dr. Christian Ottensmeier of the University of Southampton will present data relating to a prostate cancer vaccine. Dr. Richard Heller of the University of South Florida and Moffitt Cancer Center will present data on a melanoma immunotherapy study. These clinical studies are assessing safety, tolerability and immune responses of these products in conjunction with Inovio's electroporation-based DNA delivery technologies, which are designed to enhance the potency of immunotherapies including DNA vaccines.

In addition, Dr. Iacob Mathiesen of Inovio will present a general overview of electroporation delivery of immunotherapy products currently in clinical trials; Dr. Alain Rolland of Vical, Inc. will present preclinical data of a DNA vaccine for human cytomegalovirus (CMV) delivered with Inovio technology; Dr. Connie Schmaljohn of USAMRIID at Fort Detrick, MD, will present preclinical data from electroporated DNA vaccines for key biodefense targets; and Dr. Michael Eagan of Wyeth Research will present non-human primate data of an HIV vaccine currently in development with Inovio.

"Inovio has been fortunate to have collaborations with, in our opinion, some of the best scientists in the world to work with us on the development of multiple immunotherapy products delivered using our proprietary electroporation technology," stated Avtar Dhillon, MD, Inovio's CEO. "We look
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
3. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
4. Inovio: DNA delivery technology shows positive human results
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. GenoLogics Announces Bioinformatics Partnership with Illumina
7. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
8. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... Bacterin International Holdings, Inc. ("Bacterin") (OTC Bulletin Board: ... present at the upcoming OneMedForumSF 2011, Emerging Company Finance Conference, ... the Sir Francis Drake Hotel in San Francisco, CA.  Guy ... Company,s operations and its strategic positioning. Bacterin, founded ...
... ARLINGTON, Va., Jan. 3, 2011 BNA Books ... publication of the Second Edition ... upon reference available with a detailed, practitioner-oriented treatment of pharmaceutical ... the food and drug laws. (Logo: http://photos.prnewswire.com/prnh/20090529/DC24463LOGO ...
Cached Medicine Technology:Bacterin International Holdings to Present at the OneMedForum San Francisco 2011 2Bacterin International Holdings to Present at the OneMedForum San Francisco 2011 3New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law 2New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law 3
(Date:8/1/2015)... ... , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was ... National Retail Federation, the largest retail trade association in the world, for her “advocacy ... to be named as such. According to the NRF’s website, Retail Champions are “Main ...
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... an important workshop at its new True North Conference Center. The medical community, ... that the Jacksonville community may be more aligned in the effort to better ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... in Canadian hospitals, way beyond estimation, raising concern among ... investigator in the study said, “The stark reality in ... and other drug-resistant bacteria are posing a serious threat ... these super bugs are more likely to have longer ...
... a drug charity has revealed that young men are ... looks as well as to boost their self-confidence.// ... body builders and athletes to improve their performance, were ... building site workers between the ages 16 and 25. ...
... been developed by a researcher from Cornell University that detects ... in food processing.// , ‘It’s very inexpensive, it ... and it could be activated for whatever you want to ... Professor of Fibre Science and Apparel Design at Cornell. ...
... next week the distribution of a drug to help fight ... Africa is being affected by an extremely virulent strain of ... in the country. The health officials have now promised that ... next week to help fight the disease. The officials but ...
... properly for their safety and efficacy, says a ... // The drugs that are being indiscriminately prescribed ... ,The researchers analyzed drugs covered by a "congressionally ... the Food and Drug Administration (FDA) may extend ...
... branded inhalation capsules in India for the treatment of ... Beta2-agonist Formoterol and the most potent inhaled corticosteroid Fluticasone, ... 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending ... product is to be used only with the Rheohaler ...
Cached Medicine News:Health News:Nanotech Wipes for biohazard detection 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 3
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Medicine Products: